FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

U.S. stocks open with little chane as investors anxiously await more news on Trump's tariff plans, Nvidia's earnings and ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...